Lawrence Fong, MD, on Novel T-Cell Checkpoint Combinations
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Lawrence Fong, MD, of the University of California, San Francisco, discusses combination immunotherapy, now approved in melanoma, and the trials underway to explore other indications.
Limo Chen, PhD, of The University of Texas MD Anderson Cancer Center, discusses co-inhibition of CD38 and PD-L1, which leads to improved antitumor immune response, reducing tumor growth and metastasis. (Abstract 79)
Elizabeth Ann Mittendorf, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses some of the top papers presented at the ASCO-SITC Symposium and how these presentations will affect clinical practice.
Shridar Ganesan, MD, PhD, of the Rutgers Cancer Institute of New Jersey, discusses mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.
Stephen Gottschalk, MD, of Baylor College of Medicine and Texas Children’s Hospital, discusses combining CAR T cells with checkpoint blockade or targeted treatments to improve their antitumor activity in solid tumors.
Marie-Andrée Forget, PhD, of The University of Texas MD Anderson Cancer Center, discusses study findings on the impact of checkpoint blockade prior to adoptive cell therapy using tumor-infiltrating lymphocytes for metastatic melanoma. (Abstract 138)